Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (71-80 of 418) with videos related to

Pageof 42
Sort By:
BMC Cancer|March 21, 2026
The cost-effectiveness of tumour-infiltrating lymphocyte cell therapy for advanced melanoma: a systematic reviewMengjun Wu, James Larkin, Andrew Furness, et al.
The New England Journal of Medicine|March 26, 2025
Nivolumab plus Ipilimumab in Advanced Melanoma. ReplyJedd D Wolchok, F Stephen Hodi, James Larkin
Melanoma Management|September 8, 2018
Pembrolizumab in the management of metastatic melanomaLavinia Spain, Eugenie Younger, Emine Hatipoglu, et al.
Expert Opinion on Investigational Drugs|May 7, 2013
Phase I/II RAF kinase inhibitors in cancer therapySamra Turajlic, Zohra Ali, Nadia Yousaf, et al.
BJGP Open|December 20, 2018
Future career intentions of recent GP graduates in Ireland: a trend analysis studyIvana Pericin, Gerard Mansfield, James Larkin, et al.
The Lancet. Oncology|February 4, 2012
A tale of two tumours and a plea for progressRosalie Fisher, Paul Cahalin, Martin Gore, et al.
The New England Journal of Medicine|September 24, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, F Stephen Hodi, Jedd D Wolchok
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2014
Immuno-oncology combinations: a review of clinical experience and future prospectsScott J Antonia, James Larkin, Paolo A Ascierto
Lancet (London, England)|September 12, 2021
Immune checkpoint inhibitors in melanomaMatteo S Carlino, James Larkin, Georgina V Long
Expert Opinion on Drug Safety|March 7, 2014
Prospects for MEK inhibitors for treating cancerJuan Martin-Liberal, Laura Lagares-Tena, James Larkin
Pageof 42

Showing results (71-80 of 418) with videos related to

Sort By:
Pageof 42
BMC Cancer|March 21, 2026
The cost-effectiveness of tumour-infiltrating lymphocyte cell therapy for advanced melanoma: a systematic reviewMengjun Wu, James Larkin, Andrew Furness, et al.
The New England Journal of Medicine|March 26, 2025
Nivolumab plus Ipilimumab in Advanced Melanoma. ReplyJedd D Wolchok, F Stephen Hodi, James Larkin
Melanoma Management|September 8, 2018
Pembrolizumab in the management of metastatic melanomaLavinia Spain, Eugenie Younger, Emine Hatipoglu, et al.
Expert Opinion on Investigational Drugs|May 7, 2013
Phase I/II RAF kinase inhibitors in cancer therapySamra Turajlic, Zohra Ali, Nadia Yousaf, et al.
BJGP Open|December 20, 2018
Future career intentions of recent GP graduates in Ireland: a trend analysis studyIvana Pericin, Gerard Mansfield, James Larkin, et al.
The Lancet. Oncology|February 4, 2012
A tale of two tumours and a plea for progressRosalie Fisher, Paul Cahalin, Martin Gore, et al.
The New England Journal of Medicine|September 24, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, F Stephen Hodi, Jedd D Wolchok
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2014
Immuno-oncology combinations: a review of clinical experience and future prospectsScott J Antonia, James Larkin, Paolo A Ascierto
Lancet (London, England)|September 12, 2021
Immune checkpoint inhibitors in melanomaMatteo S Carlino, James Larkin, Georgina V Long
Expert Opinion on Drug Safety|March 7, 2014
Prospects for MEK inhibitors for treating cancerJuan Martin-Liberal, Laura Lagares-Tena, James Larkin
Pageof 42